BofA analyst Chi Fong lowered the firm’s price target on Roivant Sciences to $11 from $12 and keeps a Neutral rating on the shares. The firm believes the Street is mainly giving Roivant credit on its ownership of IMVT and pro forma cash discounted for burn next 12 months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ROIV:
- Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
- Roivant Sciences reports Q2 EPS (40c), consensus (31c)
- Is ROIV a Buy, Before Earnings?
- Roivant Sciences announces appointment of Sukhatme to board of directors
- JPMorgan biotech analyst to hold an analyst/industry conference call